Big Money Sentiment increased to 1.21 in 2018 Q2. It has change of 0.25, from 2018Q1’s 0.96. The ratio improved due to BMRN positioning: 30 sold and 118 reduced. 57 funds took holdings and 122 increased holdings. Investors holded 174.46 million in 2018Q1 but now own 177.65 million shares or 1.83% more. Nuwave Inv Mgmt Ltd reported 4 shs. Products Prns Limited Co reported 366,500 shs. Tekla Cap Management Ltd Limited Liability Company has 0.5% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 140,538 shs. Pictet Asset Ltd accumulated 1.44M shs. Financial Bank Of America Corp De owns 2.22 million shs for 0.03% of their capital. Hudson Bay Cap Management Lp holds 100,000 shs. 3 are held by Clarivest Asset Mgmt Llc. Regions Financial invested in 0% or 2,338 shs. Reliance Trust Of Delaware reported 5,607 shs. The Wisconsin-based Northwestern Mutual Wealth Mngmt has invested 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Senator Inv Group Ltd Partnership accumulated 1.00M shs. The South Africa-based Old Mutual Customised Solutions (Proprietary) Limited has invested 0.08% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Daiwa Secs Grp reported 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Keybank National Association Oh invested in 10,695 shs. Invesco stated it has 3.31M shs.
BMRN had 19 selling transactions and 0 buys since May 14, 2018. This’s net activity of $14.60 million. On Friday, September 14 Davis George Eric also sold $220,386 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The insider LEWIS ALAN sold $743,327. 10,000 shs were sold by SPIEGELMAN DANIEL K, worth $990,005 on Friday, June 22. $147,240 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by BIENAIME JEAN JACQUES. LAWLIS V BRYAN sold $201,068 worth of stock or 2,150 shs. On Friday, June 22 the insider Mueller Brian sold $312,928.
Based on the latest 2018Q2 regulatory filing with the SEC, Quantum Capital Management decreased its stake in Biomarin Pharmaceutical Inc (BMRN) by 63.82%. By selling 80,974 shares Quantum Capital Management made the stock popped up with 10.80%. The major pharmaceuticals company at the end of 2018Q2 was priced at $4.32 million. It’s down from 126,869 at the end of the previous reported quarter. Now it had 45,895 shares held by the institutional investor . Quantum Capital Management has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.
Another two news for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were briefly brought out by: Fool.com on October 31, 2018 with title “BioMarin Keeps on Pace for Its $2 Billion Goal”. The other Nasdaq.com‘s article was titled “Research Report Identifies Deckers Outdoor, Navient, Phillips 66, BioMarin Pharmaceutical, McKesson, and Equity …” and brought out on October 30, 2018.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage
Total analysts of 10 have positions in Biomarin Pharmaceutical (NASDAQ:BMRN) as follows: 9 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 90%. Since May 16, 2018 according to StockzIntelligence Inc Biomarin Pharmaceutical has 18 analyst reports. On Monday, August 6 the stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Outperform” rating given by Wedbush. On Friday, May 25 the rating was maintained by Credit Suisse with “Outperform”. The company rating was maintained by Wedbush on Tuesday, May 15. In Friday, August 3 report Morgan Stanley maintained the stock with “Overweight” rating. On Monday, July 9 the stock has “Outperform” rating by Credit Suisse. On Friday, May 25 the stock has “Buy” rating by Canaccord Genuity. On Monday, May 21 the rating was maintained by Wedbush with “Buy”. On Friday, October 26 the firm has “Outperform” rating given by Raymond James. On Monday, August 6 the stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Equal-Weight” rating given by Barclays Capital. In Tuesday, October 23 report Canaccord Genuity maintained the stock with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.